Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older

Peter S. Roland, Matthew W. Ryan, G. Michael Wall

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Importance of the field: Allergic rhinitis is an IgE-mediated condition that produces inflammation of the mucosa of the nose, paranasal sinuses and, frequently, of the ocular conjunctiva. Allergic rhinitis causes a significant disease burden in terms of quality of life, lost productivity and medical treatment costs. One of the newest treatments approved by the FDA is Patanase® (olopatadine hydrochloride) Nasal Spray, 665 μg/spray (OLO). Olopatadine is an antihistamine with selective H1-receptor antagonist activity. Areas covered in this review: This review details the basic and clinical research on the olopatadine molecule and OLO nasal spray from 1996 to the present day. What the reader will gain: The reader will gain a better understanding of the pharmacology of OLO nasal spray, the clinical trial data that have established the efficacy of OLO nasal spray and the overall role of OLO nasal spray in the management of allergic rhinitis. Take home message: Olopatadine nasal spray is one of the newest treatments approved by the FDA for the management of allergic rhinitis. OLO has a rapid onset of action, efficacy comparable to intranasal steroid sprays and is approved for seasonal allergic rhinitis in patients aged ≥ 6 years.

Original languageEnglish (US)
Pages (from-to)1559-1567
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume11
Issue number9
DOIs
StatePublished - Jun 2010

Fingerprint

Nasal Sprays
Seasonal Allergic Rhinitis
Therapeutics
Histamine H1 Receptors
Paranasal Sinuses
Conjunctiva
Histamine Antagonists
Nose
Health Care Costs
Immunoglobulin E
Olopatadine Hydrochloride
Mucous Membrane
Steroids
Quality of Life
Clinical Trials
Pharmacology
Inflammation
Allergic Rhinitis
Research

Keywords

  • Allergic rhinitis
  • Allergic rhinosinusitis
  • Antihistamine
  • Mast cell stabilizer
  • Nasal spray
  • Olopatadine hydrochloride
  • Patanase® Nasal Spray

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. / Roland, Peter S.; Ryan, Matthew W.; Wall, G. Michael.

In: Expert Opinion on Pharmacotherapy, Vol. 11, No. 9, 06.2010, p. 1559-1567.

Research output: Contribution to journalArticle

@article{49decbc23f2f4546b0117167dcf744b4,
title = "Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older",
abstract = "Importance of the field: Allergic rhinitis is an IgE-mediated condition that produces inflammation of the mucosa of the nose, paranasal sinuses and, frequently, of the ocular conjunctiva. Allergic rhinitis causes a significant disease burden in terms of quality of life, lost productivity and medical treatment costs. One of the newest treatments approved by the FDA is Patanase{\circledR} (olopatadine hydrochloride) Nasal Spray, 665 μg/spray (OLO). Olopatadine is an antihistamine with selective H1-receptor antagonist activity. Areas covered in this review: This review details the basic and clinical research on the olopatadine molecule and OLO nasal spray from 1996 to the present day. What the reader will gain: The reader will gain a better understanding of the pharmacology of OLO nasal spray, the clinical trial data that have established the efficacy of OLO nasal spray and the overall role of OLO nasal spray in the management of allergic rhinitis. Take home message: Olopatadine nasal spray is one of the newest treatments approved by the FDA for the management of allergic rhinitis. OLO has a rapid onset of action, efficacy comparable to intranasal steroid sprays and is approved for seasonal allergic rhinitis in patients aged ≥ 6 years.",
keywords = "Allergic rhinitis, Allergic rhinosinusitis, Antihistamine, Mast cell stabilizer, Nasal spray, Olopatadine hydrochloride, Patanase{\circledR} Nasal Spray",
author = "Roland, {Peter S.} and Ryan, {Matthew W.} and Wall, {G. Michael}",
year = "2010",
month = "6",
doi = "10.1517/14656566.2010.485609",
language = "English (US)",
volume = "11",
pages = "1559--1567",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older

AU - Roland, Peter S.

AU - Ryan, Matthew W.

AU - Wall, G. Michael

PY - 2010/6

Y1 - 2010/6

N2 - Importance of the field: Allergic rhinitis is an IgE-mediated condition that produces inflammation of the mucosa of the nose, paranasal sinuses and, frequently, of the ocular conjunctiva. Allergic rhinitis causes a significant disease burden in terms of quality of life, lost productivity and medical treatment costs. One of the newest treatments approved by the FDA is Patanase® (olopatadine hydrochloride) Nasal Spray, 665 μg/spray (OLO). Olopatadine is an antihistamine with selective H1-receptor antagonist activity. Areas covered in this review: This review details the basic and clinical research on the olopatadine molecule and OLO nasal spray from 1996 to the present day. What the reader will gain: The reader will gain a better understanding of the pharmacology of OLO nasal spray, the clinical trial data that have established the efficacy of OLO nasal spray and the overall role of OLO nasal spray in the management of allergic rhinitis. Take home message: Olopatadine nasal spray is one of the newest treatments approved by the FDA for the management of allergic rhinitis. OLO has a rapid onset of action, efficacy comparable to intranasal steroid sprays and is approved for seasonal allergic rhinitis in patients aged ≥ 6 years.

AB - Importance of the field: Allergic rhinitis is an IgE-mediated condition that produces inflammation of the mucosa of the nose, paranasal sinuses and, frequently, of the ocular conjunctiva. Allergic rhinitis causes a significant disease burden in terms of quality of life, lost productivity and medical treatment costs. One of the newest treatments approved by the FDA is Patanase® (olopatadine hydrochloride) Nasal Spray, 665 μg/spray (OLO). Olopatadine is an antihistamine with selective H1-receptor antagonist activity. Areas covered in this review: This review details the basic and clinical research on the olopatadine molecule and OLO nasal spray from 1996 to the present day. What the reader will gain: The reader will gain a better understanding of the pharmacology of OLO nasal spray, the clinical trial data that have established the efficacy of OLO nasal spray and the overall role of OLO nasal spray in the management of allergic rhinitis. Take home message: Olopatadine nasal spray is one of the newest treatments approved by the FDA for the management of allergic rhinitis. OLO has a rapid onset of action, efficacy comparable to intranasal steroid sprays and is approved for seasonal allergic rhinitis in patients aged ≥ 6 years.

KW - Allergic rhinitis

KW - Allergic rhinosinusitis

KW - Antihistamine

KW - Mast cell stabilizer

KW - Nasal spray

KW - Olopatadine hydrochloride

KW - Patanase® Nasal Spray

UR - http://www.scopus.com/inward/record.url?scp=77952687118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952687118&partnerID=8YFLogxK

U2 - 10.1517/14656566.2010.485609

DO - 10.1517/14656566.2010.485609

M3 - Article

C2 - 20482305

AN - SCOPUS:77952687118

VL - 11

SP - 1559

EP - 1567

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 9

ER -